Crystal form of acid addition salt of furopyrimidine compound

The crystalline forms of acid addition salts of the furopyrimidine compound improve solubility and stability, enabling effective pharmaceutical applications by overcoming the limitations of the amorphous form.

JP2024163194AActive Publication Date: 2024-11-21HANMI PHARM CO LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024150788
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-03-29
Filing Date
2024-09-02
Publication Date
2024-11-21
Estimated Expiration
2040-03-20

AI Technical Summary

Technical Problem

The existing form of the furopyrimidine compound, N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, is amorphous and has low water solubility, making it unsuitable for large-scale drug manufacturing and pharmaceutical applications.

Method used

The development of crystalline forms of acid addition salts, such as hydrochloride, methanesulfonate, and ethanesulfonate, which exhibit improved water solubility, stability, and non-hygroscopicity, facilitating their use in pharmaceutical compositions.

Benefits of technology

The crystalline forms of the acid addition salts enhance the physicochemical properties required for pharmaceutical use, including high solubility, stability, and ease of formulation, addressing the limitations of the amorphous form.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163194000014
    Figure 2024163194000014
  • Figure 2024163194000015
    Figure 2024163194000015
  • Figure 2024163194000016
    Figure 2024163194000016
Patent Text Reader

Abstract

To provide a crystalline form of an acid addition salt of a novel furopyrimidine compound, for example, hydrochloride, methanesulfonate, or ethanesulfonate, and a pharmaceutical composition including the same.SOLUTION: Provided are crystalline forms of acid addition salts of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and a pharmaceutical composition including the same. The crystalline forms may be easily used in preparing the pharmaceutical composition including the same as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a crystalline form of an acid addition salt of a furopyrimidine compound having a tyrosine kinase activity inhibitory effect represented by the following chemical formula 1, which is useful for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis, and a pharmaceutical composition containing the same. More specifically, the present invention relates to a crystalline form of an acid addition salt of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and a pharmaceutical composition containing the same: [ka] [Background technology]

[0002] The compound of the following formula 1, N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, is disclosed in Korean Patent Registration No. 1,589,114 and International Patent Publication No. 2011162515. The compound has an activity of selectively inhibiting mutant epidermal growth factor receptor tyrosine kinase, and is therefore useful for treating positive or malignant tumors, inflammatory diseases, or autoimmune diseases such as rheumatoid arthritis. [ka]

[0003] The reference also discloses methods for preparing compounds of Formula 1. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Republic of Korea Patent No. 1,589,114 [Patent Document 2] International Patent Publication No. 2011162515 Summary of the Invention [Problem to be solved by the invention]

[0005] However, the compound of formula 1 prepared in the references is generally prepared as an amorphous solid, which is a form that is not well suited for large-scale pharmaceutical manufacturing processes, and the compound of formula 1 prepared in the references has the disadvantage of having very low solubility in water (less than 0.001 mg / mL).

[0006] Therefore, there is a need to prepare crystalline salts of the compound of formula 1 that have improved solubility in water and are fully compatible with the stringent requirements and specifics of pharmaceutical dosage forms.

[0007] For this purpose, the present inventors have investigated the formation of acid addition salts of the compound of Chemical Formula 1 using various acids and solvents under various conditions and procedures. The present inventors have also evaluated the physicochemical properties of the acid addition salts, such as solubility, hygroscopicity, and stability. As a result, the present inventors have found that, among the acid addition salts of the compound of Chemical Formula 1, the crystalline forms of hydrochloride, methanesulfonate, and ethanesulfonate are excellent in various physicochemical properties required for pharmaceutical purposes, such as excellent solubility in water, no specific storage conditions are required, and they are stably maintained for a long period of time, and can be easily used in the preparation of pharmaceutical compositions containing them as active ingredients, thereby completing the present invention.

[0008] Accordingly, it is an object of the present invention to provide crystalline forms of acid addition salts, such as hydrochloride, methanesulfonate and ethanesulfonate salts, of the furopyrimidine compounds of formula 1, and pharmaceutical compositions containing the same. [Means for solving the problem]

[0009] In accordance with the above object, one embodiment provides a crystalline form of an acid addition salt of a compound of formula 1: [ka]

[0010] In one embodiment, the acid addition salt of the compound of Formula 1 is a hydrochloride salt.

[0011] In one embodiment, the acid addition salt of the compound of Formula 1 is a methanesulfonate salt.

[0012] In one embodiment, the acid addition salt of the compound of Formula 1 is an ethanesulfonic acid salt.

[0013] In one embodiment, the acid addition salt of the compound of Formula 1 is at least one selected from the group consisting of hydrochloride, methanesulfonate, and ethanesulfonate.

[0014] In one embodiment, the acid addition salt of the compound of Formula 1 may be in the form of anhydrous or hydrated, for example, but not limited to, the acid addition salt of the compound of Formula 1 may be a monohydrate, a dihydrate, or a trihydrate.

[0015] Specific examples of the crystalline forms are shown below: a dihydrochloride trihydrate (2HCl·3H2O) crystalline form of the compound of formula 1 having an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles (2θ±0.2°) of 6.4°, 7.1°, 12.8°, and 21.2° when irradiated with a Cu-Kα light source; a monohydrochloride dihydrate (1HCl 2H2O) crystalline form of the compound of formula 1 having an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles (2θ±0.2°) of 7.0°, 7.9°, 15.8°, 17.2°, 18.6°, 20.6°, 21.3°, and 23.2° when irradiated with a Cu-Kα light source; The monohydrochloride anhydrate (1HCl 2H2O) crystalline form of the compound of formula 1, having an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles of 4.9°, 14.8°, and 21.2° (2θ±0.2°) when irradiated with a Cu-Kα light source. a methanesulfonic anhydride (1MsOH) crystalline form of the compound of formula 1 having an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles (2θ±0.2°) of 11.8°, 17.2°, 19.0°, 20.0°, 22.8°, and 24.0° when irradiated with a Cu-Kα light source; a methanesulfonic acid monohydrate (1MsOH 1H2O) crystalline form of the compound of formula 1 having an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles (2θ±0.2°) of 7.6°, 15.2°, 17.0°, 18.7°, 20.8°, and 22.8° when irradiated with a Cu-Kα light source; and The anhydrous ethanesulfone salt (1EsOH) crystalline form of the compound of formula 1 has an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles (2θ±0.2°) of 17.1°, 18.6°, 21.3°, 22.3°, 23.0°, and 23.6° when irradiated with a Cu-Kα light source.

[0016] In one embodiment, each of the crystalline forms is in substantially pure form.

[0017] As used herein, the term "substantially pure" means at least 95% pure, preferably 99% pure, where 95% pure means that no more than 5% of the compound of Formula 1 is present in any other form (e.g., other crystalline or amorphous form), and 99% pure means that no more than 1% of the compound of Formula 1 is present in any other form (e.g., other crystalline or amorphous form).

[0018] Another aspect provides pharmaceutical compositions comprising one or more of the crystalline forms of the compound of Formula 1 and one or more pharma- ceutically acceptable carriers or diluents.

[0019] The pharmaceutical composition may also be used for the treatment of positive or malignant tumors, inflammatory diseases, or autoimmune diseases such as rheumatoid arthritis, induced by epidermal growth factor receptor tyrosine kinase or a mutant thereof. Effect of the Invention

[0020] The crystalline forms of the compound of Formula 1 according to one embodiment, such as the hydrochloride, methanesulfonate and ethanesulfonate salts, are excellent in various physicochemical properties, i.e., solubility in water, hygroscopicity, chemical stability, etc., and can be easily used in the preparation of pharmaceutical compositions containing the same as an active ingredient. [Brief description of the drawings]

[0021] [Figure 1A] FIG. 2 shows an X-ray powder diffraction (XRPD) spectrum of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 1B] FIG. 2 shows an X-ray powder diffraction (XRPD) spectrum of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 1C] FIG. 2 shows an X-ray powder diffraction (XRPD) spectrum of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 1D] FIG. 2 shows an X-ray powder diffraction (XRPD) spectrum of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 1E] FIG. 2 shows an X-ray powder diffraction (XRPD) spectrum of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 1F] FIG. 2 shows an X-ray powder diffraction (XRPD) spectrum of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 2A] 2 is a differential scanning calorimetry (DSC) graph of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 2B] 2 is a differential scanning calorimetry (DSC) graph of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 2C] 2 is a differential scanning calorimetry (DSC) graph of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 2D] 2 is a differential scanning calorimetry (DSC) graph of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 2E] 2 is a differential scanning calorimetry (DSC) graph of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 2F] 2 is a differential scanning calorimetry (DSC) graph of a crystalline form of an acid addition salt of the compound of Chemical Formula 1 according to an embodiment. [Figure 3A] 2 is a dynamic vapor sorption (DVS) graph of a crystalline form of an acid addition salt of the compound of Formula 1 according to an embodiment. [Figure 3B] 2 is a dynamic vapor sorption (DVS) graph of a crystalline form of an acid addition salt of the compound of Formula 1 according to an embodiment. [Figure 3C] 2 is a dynamic vapor sorption (DVS) graph of a crystalline form of an acid addition salt of the compound of Formula 1 according to an embodiment. [Figure 3D] 2 is a dynamic vapor sorption (DVS) graph of a crystalline form of an acid addition salt of the compound of Formula 1 according to an embodiment. [Figure 3E] 2 is a dynamic vapor sorption (DVS) graph of a crystalline form of an acid addition salt of the compound of Formula 1 according to an embodiment. [Figure 3F] 2 is a dynamic vapor sorption (DVS) graph of a crystalline form of an acid addition salt of the compound of Formula 1 according to an embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] Terms not specifically defined herein have the meanings that would be given them by one of ordinary skill in the art in light of the description and context. However, unless specifically stated otherwise, throughout this specification the following terms have the meanings indicated below:

[0023] The term "about" means within 5%, preferably within 1% to 2%, of a given value or range. For example, "about 10%" means 9.5% to 10.5%, preferably 9.8% to 10.2%. As another example, "about 100°C" means 95°C to 105°C, preferably 98°C to 102°C.

[0024] Unless otherwise specified, those skilled in the art will understand that the peak values ​​from X-ray powder diffraction studies reported in the present invention are typically associated with experimental error observable in the art. Specifically, the peaks are understood to be located within ±0.5° of the values ​​reported herein. More specifically, the peaks are understood to be located within ±0.2° of the values ​​reported herein.

[0025] The term "acid addition salt" refers to a salt with an inorganic acid or an organic acid capable of forming a salt by an acid-base reaction with the compound of Chemical Formula 1. Examples of inorganic acids used to form the acid addition salt include hydrochloride, bromate, sulfate, phosphate, and nitrate, and examples of organic acids include maleate, fumarate, citrate, succinate, oxalic acid, tartaric acid, methanesulfonate, ethanesulfonic acid, benzenesulfonate, p-toluenesulfonate, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, and (+)-camphor-10-sulfonate.

[0026] The hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of formula 1, and their crystalline forms Provided are the hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of formula 1 below, i.e., N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and crystalline forms thereof: [ka]

[0027] The compound of Formula 1 can also be prepared according to the general procedures described in Korean Patent Registration No. 1,589,114 and International Patent Publication No. 2011162515, the entire contents of which are incorporated herein by reference.

[0028] The compound of formula 1 described in the above document is amorphous and poorly soluble in water, with a solubility of less than 0.001 mg / mL.

[0029] It is generally known that conversion of a free base into a salt form helps to solubilize poorly water-soluble drug substances, but such salts must have various physicochemical properties required for pharmaceutical purposes, such as reproducibility of the preparation of a specific crystal form, high crystallinity, stability of the crystal form, chemical stability, and non-hygroscopicity.

[0030] In order to select a suitable salt form of the compound of Chemical Formula 1, various conditions and procedures were used with various acids and solvents to investigate the salt formation of the compound of Chemical Formula 1, and the physicochemical properties such as solubility, hygroscopicity and stability of the salts formed were evaluated. Among the salts thus prepared, the crystal forms of the hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of Chemical Formula 1 were found to be the most excellent in terms of various physicochemical properties such as reproducibility of the preparation of specific crystal forms required for pharmaceutical purposes, purity improvement, high crystallinity, stability of crystal forms, chemical stability and non-hygroscopicity.

[0031] Crystalline forms of the hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of formula 1 The salt of the compound of formula 1 may be prepared in a crystalline or amorphous form, or in a mixture thereof, but is preferably in a crystalline form. The crystalline forms of the hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of formula 1 are preferred in that they have excellent physicochemical properties that allow for easy formulation and excellent stability.

[0032] According to the present invention, the compound of Formula 1 can be in the form of various crystalline acid addition salts, for example, the dihydrochloride trihydrate (2HCl·3H2O) crystal form, the monohydrochloride dihydrate (1HCl·2H2O) crystal form, the monohydrochloride anhydrous (1HCl) crystal form, the methanesulfonate anhydrous (1MsOH) crystal form, the methanesulfonate monohydrate (1MsOH·1H2O) crystal form, and the ethanesulfonate anhydrous (1EsOH) crystal form of the compound of Formula 1.

[0033] As a result of the investigation in the following Test Example 1, among the above crystalline acid addition salts, the dihydrochloride trihydrate (2HCl·3H2O), methanesulfonate anhydrous (1MsOH) crystal form, methanesulfonate monohydrate (1MsOH·1H2O) crystal form, and ethanesulfonate anhydrous (1EsOH) crystal form were superior in terms of solubility in water, with the ethanesulfonate anhydrous (1EsOH) crystal form being the most superior in terms of solubility. The above acid addition salts are advantageous in terms of non-hygroscopicity / non-dehygroscopicity and stability, and are therefore also useful substances as active ingredients in pharmaceutical compositions.

[0034] Each of the above-mentioned crystal forms according to the present invention will now be described in more detail.

[0035] According to one embodiment, the present invention provides a dihydrochloride trihydrate (2HCl·3H2O) crystalline form of the compound of formula 1, which has an X-ray powder diffraction (XRPD) spectrum including peaks at diffraction angles (2θ±0.2°) of 6.4°, 7.1°, 11.1°, 12.8°, and 21.2° when irradiated with a Cu-Kα light source. More specifically, the dihydrochloride trihydrate (2HCl·3H2O) crystalline form of the compound of formula 1 can have an XRPD spectrum including peaks at diffraction angles (2θ±0.2°) of 6.4°, 7.1°, 12.8°, 15.6°, 19.6°, 21.2°, 27.9°, and 28.3° when irradiated with a Cu-Kα light source. These peaks also have a relative intensity of about 10% or more.

[0036] The dihydrochloride trihydrate (2HCl·3H2O) crystal form of the compound of formula 1 may have a water content of about 8.5% to 9.5% (theoretical water content 9.04%) and a melting point of about 210°C to 220°C. The crystal form may have two endothermic peaks in the vicinity of about 75°C to 80°C and about 105°C to 110°C in DSC (10°C / min), which indicate the dehydration point of the trihydrate. The crystal form may have an endothermic peak at about 200°C to 220°C, which indicates the melting point. The crystal form may have an exothermic peak at about 240°C to 250°C, which indicates thermal decomposition. In dynamic vapor sorption (DVS) of the crystal form, moisture absorption occurs in the range of 10% to 20% relative humidity, and very low moisture absorption can be measured in the range of 30% to 90% relative humidity.

[0037] According to one embodiment, the present invention provides a monohydrochloride dihydrate (1HCl·2H2O) crystalline form of the compound of formula 1, the crystalline form having an X-ray powder diffraction (XRPD) spectrum comprising peaks at diffraction angles (2θ±0.2°) of 7.0°, 7.9°, 15.8°, 17.2°, 18.6°, 20.6°, 21.3°, and 23.2° when illuminated with a Cu-Kα light source. More specifically, the monohydrochloride dihydrate (1HCl 2H2O) crystalline form of the compound of Formula 1, when illuminated with a Cu-Kα light source, can have an XRPD spectrum including peaks at diffraction angles (2θ±0.2°) of 7.0°, 7.9°, 12.6°, 15.8°, 17.2°, 18.6°, 20.2°, 20.6°, 21.0°, 21.3°, 23.2°, 26.9°, and 28.9°, which peaks have a relative intensity of about 25% or greater.

[0038] The monohydrochloride dihydrate (1HCl·2H2O) crystal form of the compound of Formula 1 may have an endothermic peak at about 110°C to 140°C in DSC (10°C / min), which represents the dehydration point of the dihydrate. It may have an endothermic peak at about 160°C to 170°C, which represents the melting point. The crystal form may have a water content of about 6.5% to 7.5% (theoretical water content 6.63%) and a melting point of about 150°C to 170°C. The crystal form may have a very low moisture absorption in the range of 10% to 90% relative humidity in DVS.

[0039] According to one embodiment, the present invention provides a monohydrochloride anhydrate (1HCl) crystalline form of the compound of formula 1, which has an X-ray powder diffraction (XRPD) spectrum including peaks at diffraction angles (2θ±0.2) of 4.9°, 14.8°, and 21.2° when irradiated with a Cu-Kα light source. More specifically, the monohydrochloride anhydrate (1HCl) crystalline form of the compound of formula 1 can have an XRPD spectrum including peaks at diffraction angles (2θ±0.2) of 4.9°, 12.2°, 14.8°, 21.2°, 23.1°, and 24.9° when irradiated with a Cu-Kα light source, which peaks have a relative intensity of about 5% or more.

[0040] The monohydrochloride anhydrous (1HCl) crystalline form of the compound of Formula 1 may have an endothermic peak at about 250° C. to 270° C. in DSC (10° C. / min), which means the melting point. The crystalline form may have a moisture content of about 0.1% to 1.0% (theoretical moisture content 0%) and a melting point of about 255° C. to 270° C. The crystalline form may have a very low moisture absorption in the range of 10% to 90% relative humidity in DVS.

[0041] According to one embodiment, the present invention provides a methanesulfonic anhydride (1MsOH) crystalline form of the compound of Formula 1, the crystalline form having an X-ray powder diffraction (XRPD) spectrum comprising peaks at diffraction angles (2θ±0.2°) of 11.8°, 17.2°, 19.0°, 20.0°, 22.8°, and 24.0° when irradiated with a Cu-Kα light source. More specifically, the methanesulfonic anhydride (1MsOH) crystalline form of the compound of Formula 1 may have an XRPD spectrum including peaks at diffraction angles (2θ±0.2°) of 10.7°, 11.3°, 11.8°, 12.2°, 15.0°, 17.2°, 17.6°, 18.6°, 19.0°, 20.0°, 22.3°, 22.8°, 23.3°, 23.7°, and 24.0° when irradiated with a Cu-Kα light source, the peaks also having a relative intensity of about 15% or more.

[0042] The methanesulfonic anhydride (1MsOH) crystal form of the compound of Formula 1 may have a water content of about 0.5% to 1.5% (theoretical water content: 0%) and a melting point of about 235° C. to 245° C. The crystal form may have an endothermic peak at about 235° C. to 240° C. in DSC (10° C. / min), which represents the melting point. In DVS of the crystal form, a water absorption of 2% to 3% may be measured in the range of relative humidity from 10% to 90%.

[0043] According to one embodiment, the present invention provides a methanesulfonic acid monohydrate (1MsOH·1H2O) crystalline form of the compound of formula 1, the crystalline form having an X-ray powder diffraction (XRPD) spectrum comprising peaks at diffraction angles (2θ±0.2°) of 7.6°, 15.2°, 17.0°, 18.7°, 20.8°, and 22.8° when illuminated with a Cu-Kα light source. More specifically, the methanesulfonic acid monohydrate (1MsOH·1H2O) crystalline form of the compound of Formula 1 may have an XRPD spectrum including peaks at diffraction angles (2θ±0.2°) of 7.6°, 8.8°, 15.2°, 17.0°, 17.8°, 18.4°, 18.7°, 20.1°, 20.8°, 21.0°, 22.1°, 22.8°, 24.6°, 24.9°, 25.4°, 26.1°, 26.5°, 27.0°, and 28.4°, which peaks have a relative intensity of about 15% or greater, when illuminated with a Cu-Kα light source.

[0044] The methanesulfonic acid monohydrate (1MsOH·1H2O) crystal form of the compound of Formula 1 may have an endothermic peak at about 90°C to 95°C in DSC (10°C / min), which represents the dehydration point of the monohydrate. It may have an endothermic peak at about 205°C to 210°C, which represents the melting point. The crystal form may have a moisture content of about 2.5% to 3.5% (theoretical moisture content 3.08%) and a melting point of about 200°C to 210°C. The crystal form may have a very low moisture absorption in the range of 10% to 90% relative humidity in DVS.

[0045] According to one embodiment, the present invention provides a crystalline form of the anhydrous ethanesulfonic acid salt (1EsOH) of the compound of Formula 1, the crystalline form having an X-ray powder diffraction (XRPD) spectrum including peaks at diffraction angles (2θ±0.2) of 17.1°, 18.6°, 21.3°, 22.3°, 23.0°, and 23.6° when irradiated with a Cu-Kα light source. More specifically, the ethanesulfone salt anhydrate (1EsOH) crystal form of the compound of Chemical Formula 1 may have an XRPD spectrum including peaks at diffraction angles (2θ±0.2) of 7.1°, 11.1°, 11.7°, 14.2°, 17.1°, 18.1°, 18.6°, 19.8°, 20.0°, 21.3°, 22.3°, 23.0°, and 23.6° when irradiated with a Cu-Kα light source, which peaks have a relative intensity of about 15% or more.

[0046] The ethanesulfonic acid salt anhydride (1EsOH) crystal form of the compound of Chemical Formula 1 may have an endothermic peak at about 230° C. to 240° C. in DSC (10° C. / min), which means the melting point. The crystal form may have a moisture content of about 0.1% to 1.0% (theoretical moisture content 0%) and a melting point of about 230° C. to 240° C. The moisture absorption of the crystal form may be very low, less than 1%, in the range of 10% to 90% relative humidity in DVS.

[0047] Pharmaceutical Compositions As disclosed in Korean Patent Registration No. 1,589,114 and International Patent Publication No. 2011162515, the compound of Chemical Formula 1 has been demonstrated to selectively and effectively inhibit the growth and drug resistance of cancer cells induced by epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof.

[0048] From this perspective, the crystalline hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of Chemical Formula 1 can also be used to prepare a pharmaceutical composition for treating or preventing positive or malignant tumors, inflammatory diseases, or autoimmune diseases such as rheumatoid arthritis induced by epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof.

[0049] Accordingly, the present invention provides a pharmaceutical composition comprising the crystalline hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of Formula 1 and one or more pharma- ceutically acceptable carriers or diluents, which may be used for the treatment of cancer, tumors, inflammatory diseases, or autoimmune diseases such as rheumatoid arthritis induced by epidermal growth factor receptor tyrosine kinase or a mutant thereof.

[0050] The dosage of the crystalline hydrochloride, methanesulfonate and ethanesulfonate salts of the compound of formula 1 or pharmaceutical compositions containing the same will vary depending on the subject being treated, the severity of the disease or condition, the rate of administration, and the judgment of the prescribing physician, but generally, based on the compound of formula 1, the active ingredient is administered to a human in an amount of 10 mg to 2,000 mg, preferably 50 mg to 1,000 mg, as the free base of the compound of formula 1, based on a body weight of 70 kg, once to four times a day, or on / off schedule, via oral or parenteral routes. In some cases, dosages lower than the above ranges may be more suitable, and higher dosages may be used without causing adverse side effects, and in the case of higher dosages, they may be distributed into several small dosages over the course of a day.

[0051] The pharmaceutical compositions according to the present invention can be formulated by conventional methods into a variety of oral dosage forms, such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, or parenteral dosage forms, such as intramuscular, intravenous or subcutaneous administration.

[0052] The pharmaceutical composition may contain any common non-toxic pharma- ceutically acceptable carrier, diluent, adjuvant, excipient, etc. When the pharmaceutical composition according to the present invention is prepared in the form of an oral dosage form, examples of the carrier used include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactant, suspending agent, emulsifier, diluent, etc. When the pharmaceutical composition according to the present invention is prepared in the form of an oral dosage form, examples of the diluent used include lactose, mannitol, sugar, microcrystalline cellulose and cellulose derivatives, and dried corn starch, etc. When the pharmaceutical composition according to the present invention is prepared in the form of an injection, the carrier may be water, saline, glucose solution, analogous sugar solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride, surfactant, suspending agent, emulsifier, etc.

[0053] Also provided is a method for treating a disease comprising administering to an individual a therapeutically effective amount of the crystalline form or pharmaceutical composition of the compound of formula 1. The disease may be a positive or malignant tumor, an inflammatory disease, or an autoimmune disease such as rheumatoid arthritis.

[0054] The present invention will be described below with reference to specific examples. However, the following examples are merely for the purpose of illustrating the present invention, and the scope of the present invention is not limited thereto. EXAMPLES

[0055] Analytical instruments and measurement methods 1. X-ray powder diffraction (XRPD) X-ray powder diffraction spectroscopy (XRPD) analysis was performed on a D8 Advance (Bruker ASX, Germany) analyzer from 3°2θ to 40°2θ. If the amount of sample was less than 100 mg, about 5 mg to 10 mg of sample was gently pressed onto a glass slide fitted into a sample holder. If the amount of sample was more than 100 mg, about 100 mg of sample was gently pressed onto a plastic sample holder so that the sample surface was smooth and just above the sample holder level. The measurements were carried out as follows: Anode material (Ka): Cu Ka (1.54056 Å) Scan range: 3° to 40° Generator setting: 100mA, 40.0kV Scan speed: 1sec / step Divergence slit size: 0.3 degrees Anti-scatter slit: 0.3 degree Temperature:20℃ Step size: 0.02 deg 2θ Rotating: Use Goniometer radius: 435mm

[0056] 2. Differential Scanning Calorimetry (DSC) Differential scanning calorimetry (DSC) analysis was performed on a STA-1000 (Scinco, Korea) analyzer at 30° C. to 350° C. 5 mg to 10 mg of sample was weighed into an aluminum DSC pan and non-hermetically sealed with a perforated aluminum lid, after which the sample was heated from 30° C. to 350° C. at a scan rate of 10° C. / min to monitor the generated heat flow response (DSC).

[0057] 3. Dynamic Vapor Sorption (DVS) Dynamic vapor sorption (DVS) analysis was performed on a DVS advantage (surface measurement system, UK) analyzer at 25°C and 0% to 90% relative humidity. 10 mg of sample was placed in a wire mesh vapor sorption balance pan and attached to a DVS-advantage dynamic vapor sorption balance by surface measurement systems. The sample was subjected to a ramping profile from 10% to 90% relative humidity (RH) in 10% increments, with the sample held at each step until a stable weight was achieved (99.5% step completed). After completing the adsorption cycle, the sample was dried using the same process, but held at 0% or less relative humidity. The weight change during the adsorption / desorption cycle (replicated three times) was recorded to measure the hygroscopicity of the sample.

[0058] 4. High Performance Liquid Chromatography (HPLC) High performance liquid chromatography (HPLC) analysis was performed using an Agilent 1100 / 1200 series HPLC Systems (Agilent, USA) analyzer for the purpose of purity analysis and content analysis such as stability testing, and the HPLC analysis conditions were as follows. Conditions for purity analysis and content analysis: Furopyrimidine compound of formula 1 Column: Hydrosphere C18 (YMC), 5 μm (150 mm × 4.6 mm) Column temperature: 30℃ Detector: Ultraviolet absorption spectrophotometer Detection wavelength: 254 nm Flow rate: 1.0mL / min Analysis time: 35 minutes Eluent: NaClO4-NaH2PO4-phosphate buffer solution (pH 2.5±0.1) / CH3CN=65 / 35(v / v%)

[0059] 5. Ion Chromatography (IC) Ion chromatography (IC) analysis was performed using a Thermo Fisher Scientific ICS-2500 series IC systems (Thermo Fisher Scientific, USA) analyzer to analyze the hydrochloric acid content of the hydrochloride salt, and the IC analysis conditions were as follows. Content analysis conditions: furopyrimidine compound of formula 1 Column: IonPac AS19 (Dionex), (25 mm x 4 mm), guard (50 mm x mm) Column temperature: 30℃ Detector: Electrical conductivity detector (CD) Suppressor: ASRS 4mm, current 40mA Flow rate: 1.0mL / min Analysis time: 30 minutes Eluent: 10 mM potassium hydroxide solution

[0060] 6. Moisture Measurement Moisture measurements were performed using a 795KFT Titrino (Metrohm, Switzerland) Karl Fischer moisture meter.

[0061] 7. Melting Point Measurement The melting point was measured using an IA9200 (Electrothermal, UK) melting point apparatus.

[0062] Example: Preparation and Analysis of Crystalline Forms of Acid Addition Salts of Compound of Formula 1

[0063] Example 1. Dihydrochloride trihydrate (2HCl 3H 2 O) Preparation of Crystalline Forms 690g (1.47mol) of the compound of formula 1 prepared by the method of Korean Patent Registration No. 1,589,114 and International Patent Publication No. 2011162515 cited herein or a method similar thereto was added to 6,900mL of 80% aqueous isopropanol solution (isopropanol / water = 8 / 2). 240mL (2.93mol) of concentrated hydrochloric acid was added to the reaction solution, which was then stirred at room temperature for 12 hours. The reaction solution was cooled to 10°C, and the precipitated solid was filtered. The solid was washed with 690mL of 80% aqueous isopropanol solution (isopropanol / water = 8 / 2) and dried to obtain 650g of the title compound (yield: 82.0%). Moisture content: 8.8% (theoretical value for trihydrate: 9.04%) Ion chromatography: 13.6% (dihydrochloride theoretical value: 13.4%)

[0064] Characteristic analysis The results of XRPD analysis, DSC analysis and DVS analysis of the crystalline form prepared in Example 1 are shown in FIG. 1A, FIG. 2A and FIG. 3A, respectively. In the XRPD spectrum of the crystalline form, the relative intensity (I / I o The peaks with I / I of 3% or more are shown in Table 1 below. o The peaks with a ratio of 10% or more were observed at diffraction angles (2θ±0.2°) of 6.4°, 7.1°, 12.8°, 15.6°, 19.6°, 21.2°, 27.9 and 28.3°.

[0065] [Table 1]

[0066] DSC (10° C. / min) of the crystalline form showed endothermic peaks with an onset of about 58.7° C. and minima at about 77.4° C. and about 109.4° C., endothermic peaks at about 200.1° C. and about 218.7° C., and an exothermic peak at about 250° C. The DSC endothermic peaks at about 77.4° C. and about 109.4° C. represent the dehydration point of the dihydrochloride trihydrate crystalline form, the endothermic peaks at about 200.08° C. and about 218.69 represent the melting point, and the exothermic peak at about 250° C. represents thermal decomposition.

[0067] The crystalline form exhibited a moisture content of about 8.8% (theoretical moisture content 9.04%) by Karl Fischer titration and a melting point of about 210°C to 218°C.

[0068] In the crystalline form of DVS, moisture absorption occurs in the range of 0% to 20% relative humidity, but the degree of moisture absorption is very low in the range of 30% or more relative humidity. The crystalline form was sufficiently stable under long-term storage conditions (e.g., 25°C and 60% relative humidity), accelerated conditions (e.g., 40°C and 75% relative humidity), and harsh conditions (e.g., 40°C and 75% relative humidity).

[0069] Example 2. Monohydrochloride dihydrate (1HCl 2H 2 O) Preparation of Crystalline Forms Example 2.1. Compound of formula 1 dihydrochloride trihydrate (2HCl 3H 2 O) from 460g (0.85mol) of the compound of formula 1 dihydrochloride trihydrate (2HCl·3H2O) was added to 4,600mL of 50% aqueous ethanol solution (ethanol / water=5 / 5). The reaction solution was heated to 40℃ to 45℃, and an aqueous solution of 67.7g (1.69mol) of sodium hydroxide dissolved in 460mL of water was added, and the mixture was stirred at 40℃ to 45℃ for 30 minutes. 89.7mL (1.02mol) of concentrated hydrochloric acid was added to the reaction solution, and the mixture was stirred at 40℃ to 45℃ for 1 hour. The reaction solution was gradually cooled to 20℃ to 25℃, and stirred at 20℃ to 25℃ for 12 hours. The precipitated solid was filtered, washed with 460mL of cooled 50% aqueous ethanol solution (ethanol / water=5 / 5), and then dried to obtain 398g of the title compound (yield: 87.0%). Moisture content: 7.5% (dihydrate theoretical value: 6.63%) Ion chromatography: 7.4% (monohydrochloride theoretical value: 7.2%)

[0070] Example 2.2. Preparation from compound of formula 1 53g (0.11mol) of the compound of formula 1 was added to 530mL of 80% aqueous methanol solution (methanol / water = 8 / 2). 10.9mL (0.12mol) of concentrated hydrochloric acid was added to the reaction solution, and the mixture was stirred at 20°C to 25°C for 12 hours. The precipitated solid was filtered, washed with 53mL of 80% aqueous methanol solution (methanol / water = 8 / 2), and then dried at 50°C to obtain 49g of the title compound (yield: 80.0%). Moisture content: 6.2% (dihydrate theoretical value: 6.63%) Ion chromatography: 7.0% (monohydrochloride theoretical value: 7.2%)

[0071] Characteristic analysis The results of XRPD analysis, DSC analysis and DVS analysis of the crystalline form prepared in Example 2 are shown in FIG. 1Bb, FIG. 2B and FIG. 3B, respectively. In the XRPD spectrum of the crystalline form, the relative intensity (I / I o The peaks with I / I of 5% or more are shown in Table 2 below. o In the case of peaks with a ratio of 10% or more, the diffraction angles (2θ±0.2°) were 7.0°, 7.9°, 12.6°, 13.4°, 15.5°, 15.8°, 17.2°, 18.2°, 18.6°, 19.1°, 20.2°, 20.6°, 21.0°, 21.3°, 22.1°, 23.2°, 23.8°, 24.1°, 24.8°, 25.0°, 25.3°, 25.9°, 26.9°, 28.1°, 28.9°, 30.1°, 30.7°, 31.2°, 32.2 and 33.9°.

[0072] [Table 2]

[0073] DSC (10° C. / min) of the crystalline form showed endothermic peaks at about 115.0° C. and 135.8° C., and an endothermic peak at about 165.1° C. The endothermic peaks at about 115.0° C. and 135.8° C. in the DSC represent the dehydration point of the monohydrochloride dihydrate crystalline form, and the endothermic peak at about 165.1° C. represents the melting point. The crystalline form exhibited a moisture content of about 7.5% (theoretical moisture content 6.63%) by Karl Fischer titration and a melting point of about 154°C to 165°C. In the DVS of the crystalline form, the moisture absorption level was measured to be as low as about 0.8% in the range of relative humidity from 10% to 90%. The crystalline form was sufficiently stable under long-term storage conditions (e.g., temperature of 25° C. and relative humidity of 60%) and accelerated conditions (e.g., temperature of 40° C. and relative humidity of 75%).

[0074] Example 3. Preparation of the monohydrochloride anhydrate (1HCl·anhydrate) crystalline form of the compound of formula 1 Example 3.1. Compound of formula 1 dihydrochloride trihydrate (2HCl 3H 2 O) from 70 g of the dihydrochloride trihydrate (2HCl·3H2O) of the compound of formula 1 was added to 2,100 mL of water. The reaction solution was stirred at room temperature for 2 hours, and the precipitated solid was filtered. It was washed with 70 mL of water and dried to obtain 25 g of the title compound (yield: 35.7%). Moisture: 0.3% Ion chromatography: 7.1% (monohydrochloride theoretical value: 7.2%)

[0075] Example 3.2. Preparation from compound of formula 1 53 g (0.11 mol) of the compound of formula 1 was added to 530 mL of methanol. 10.9 mL (0.12 mol) of concentrated hydrochloric acid was added to the reaction solution, and the mixture was stirred at 20° C. to 25° C. for 12 hours. The precipitated solid was filtered, washed with 53 mL of methanol, and then dried at 50° C. to obtain 46 g of the title compound (yield: 81.0%). Moisture content: 0.4% Ion chromatography: 7.2% (monohydrochloride theoretical value: 7.2%)

[0076] Characteristic analysis The results of XRPD analysis, DSC analysis and DVS analysis of the crystalline form prepared in Example 3 are shown in FIG. 1C, FIG. 2C and FIG. 3C, respectively. In the XRPD spectrum of the crystalline form, the relative intensity (I / I o The peaks with I / I of 2% or more are shown in Table 3 below. o The peaks with a ratio of 5% or more were observed at diffraction angles of 4.9°, 12.2°, 14.8°, 21.2°, 23.1°, and 24.9° (2θ±0.2°).

[0077] [Table 3]

[0078] The crystalline form showed an endothermic peak at about 264.2° C. in DSC (10° C. / min). The endothermic peak at about 264.2° C. in DSC indicates the melting point.

[0079] The crystalline form exhibited a water content of about 0.3% by Karl Fischer titration and a melting point of about 259-264°C.

[0080] In the DVS of the crystalline form, the moisture absorption level was measured to be as low as about 1% in the range of relative humidity from 10% to 90%. The crystalline form was sufficiently stable under long-term storage conditions (e.g., temperature of 25° C. and relative humidity of 60%) and accelerated conditions (e.g., temperature of 40° C. and relative humidity of 75%).

[0081] Example 4. Preparation of methanesulfonate anhydrate of the compound of formula 1 10 g (21.26 mmol) of the compound of Formula 1 was added to 100 mL of ethanol. 1.52 mL (23.38 mmol) of methanesulfonic acid was added dropwise to the reaction solution, and the mixture was stirred at 20°C to 25°C for 12 hours, after which the precipitated solid was filtered. The filtered product was washed with 10 mL of ethanol and dried at 50°C to obtain 10 g of the title compound (yield: 83.0%). Moisture: 1.0%

[0082] Characteristic analysis The results of XRPD analysis, DSC analysis, and DVS analysis of the crystalline form of the methanesulfonate anhydrate (MsOH·anhydrate) of compound of Formula 1 prepared in Example 4 are shown in FIG. 1D, FIG. 2D, and FIG. 3D, respectively. In the XRPD spectrum of the crystalline form, the relative intensity (I / I o The peaks with I / I of 5% or more are shown in Table 4 below. o In the case of peaks with a ratio of 10% or more, the diffraction angles (2θ±0.2°) were 7.1°, 10.7°, 11.3°, 11.8°, 12.2°, 14.2°, 15.0°, 17.2°, 17.6°, 18.1°, 18.6°, 19.0°, 20.0°, 21.4°, 22.3°, 22.8°, 23.3°, 23.7°, 24.0°, 24.7°, 27.5°, 27.7°, and 30.3°.

[0083] [Table 4]

[0084] The crystalline form showed an endothermic peak at about 242.5° C. in DSC (10° C. / min). The endothermic peak at about 242.5° C. in DSC indicates the melting point.

[0085] The crystalline form exhibited a moisture content of about 1.0% by Karl Fischer titration and a melting point of about 237-242°C.

[0086] In the DVS of the crystalline form, the moisture uptake was measured to be as low as about 2% in the range of 10% to 90% relative humidity.The crystalline form was sufficiently stable under long-term storage conditions (e.g., temperature of 25°C and 60% relative humidity) and accelerated conditions (e.g., temperature of 40°C and 75% relative humidity).

[0087] Example 5. Methanesulfonate monohydrate of the compound of formula 1 (mesylate·1H 2 O) Production 10 g (21.26 mmol) of the compound of formula 1 was added to 100 mL of 90% aqueous ethanol solution (ethanol / water = 9 / 1). 1.52 mL (23.38 mmol) of methanesulfonic acid was added dropwise to the reaction solution, and the mixture was stirred at 20 to 25°C for 12 hours, after which the precipitated solid was filtered. The filtered product was washed with 10 mL of ethanol and dried at 50°C to obtain 10.9 g of the title compound (yield: 91.0%). Moisture content: 3.1% (monohydrate theoretical value: 3.08%)

[0088] Characteristic analysis The results of XRPD analysis, DSC analysis and DVS analysis of the crystalline form of methanesulfonate monohydrate (MsOH·1H2O) of compound of Formula 1 prepared in Example 5 are shown in Figures 1E, 2E and 3E, respectively.

[0089] In the XRPD spectrum of the crystalline form, the relative intensity (I / I o The peaks with I / I of 5% or more are shown in Table 5 below. o In the case of peaks with a ratio of 10% or more, the diffraction angles (2θ±0.2°) were 7.6°, 8.8°, 12.3°, 13.1°, 14.9°, 15.2°, 17.0°, 17.8°, 18.4°, 18.7°, 19.7°, 20.1°, 20.8°, 21.0°, 22.1°, 22.8°, 24.6°, 24.9°, 25.4°, 26.1°, 26.5°, 27.0°, 27.4°, 28.4°, 28.8°, 29.7°, and 30.5°.

[0090] [Table 5]

[0091] DSC (10° C. / min) of the crystalline form showed an endothermic peak at about 92.0° C. and an endothermic peak at about 209.0° C. The endothermic peak at about 92.0° C. in the DSC represents the dehydration point of the methanesulfonate monohydrate crystalline form, and the endothermic peak at about 209.0° C. represents the melting point.

[0092] The crystalline form showed a moisture content of about 3.1% (theoretical moisture content 3.08%) by Karl Fischer titration and a melting point of about 204°C to 208°C.

[0093] In the DVS of the crystalline form, the moisture absorption level was measured to be as low as about 1% in the range of relative humidity from 10% to 90%. The crystalline form was sufficiently stable under long-term storage conditions (e.g., temperature of 25° C. and relative humidity of 60%) and accelerated conditions (e.g., temperature of 40° C. and relative humidity of 75%).

[0094] Example 6. Preparation of the ethanesulfonate anhydrate crystalline form of the compound of formula 1 Example 6.1. Preparation in absolute ethanol 10 g (21.26 mmol) of the compound of formula 1 was added to 100 mL of ethanol. 1.92 mL (23.38 mmol) of ethanesulfonic acid was added dropwise to the reaction solution, and the mixture was stirred at 20°C to 25°C for 3 hours, after which the precipitated solid was filtered. The filtered product was washed with 10 mL of ethanol and dried at 50°C to obtain 10.5 g of the title compound (yield: 85.0%). Moisture: 0.3%

[0095] Example 6.2. Preparation in aqueous ethanol 10 g (21.26 mmol) of the compound of formula 1 was added to 100 mL of 90% aqueous ethanol solution (ethanol / water = 9 / 1). 1.92 mL (23.38 mmol) of ethanesulfonic acid was added dropwise to the reaction solution, and the mixture was stirred at 20 to 25°C for 3 hours, after which the precipitated solid was filtered. The filtered product was washed with 10 mL of ethanol and dried at 50°C to obtain 8.9 g of the title compound (yield: 73.0%). Moisture content: 0.2%

[0096] Characteristic analysis The results of XRPD analysis, DSC analysis and DVS analysis of the ethanesulfonate anhydrate crystal form of the compound of Formula 1 prepared in Example 6 are shown in Figures 1F, 2F and 3F, respectively.

[0097] In the XRPD spectrum of the crystalline form, the relative intensity (I / I o The peaks with a I / I ratio of 10% or more are shown in Table 6 below. o The peaks with a ratio of 10% or more were observed at diffraction angles (2θ±0.2) of 7.1°, 11.1°, 11.7°, 12.2°, 14.2°, 14.9°, 17.1°, 18.1°, 18.6°, 19.8°, 20.0°, 21.3°, 22.3°, 23.0°, 23.6 and 27.6°.

[0098] [Table 6]

[0099] The crystalline form showed an endothermic peak at about 235.2° C. in DSC (10° C. / min). The endothermic peak at about 235.2° C. in DSC indicates the melting point.

[0100] The crystalline form exhibited a moisture content of 0.3% by Karl Fischer titration and a melting point of about 229-235°C.

[0101] In the DVS of the crystalline form, the moisture absorption level was measured to be as low as about 1% in the range of relative humidity from 10% to 90%, and the crystalline form was therefore sufficiently stable under long-term storage conditions (temperature of 25°C and relative humidity of 60%) and accelerated conditions (e.g., temperature of 40°C and relative humidity of 75%).

[0102] Test Example 1. Water solubility measurement test To measure the water solubility, each of the acid addition salts of the compound of Formula 1 prepared in Examples 1 to 6 was prepared in deionized water under the following conditions, and each solution was analyzed by high performance liquid chromatography (HPLC) according to the content measurement conditions of the compound of Formula 1. The amount of the compound of Formula 1 dissolved was measured (LOD: more than 0.001 mg / mL) and converted, and the results are shown in Tables 7 and 8 below.

[0103] Specifically, 100 mg of each polymorph was added to 5 mL of water and mixed using a voltamixer at 20°C to 25°C, and then filtered using a GH Polypro membrane Acrodisc, PALL (pore size 0.2 μm). The filtrate was diluted with a dilution solvent for high performance liquid chromatography (HPLC) analysis to prepare the sample.

[0104] [Table 7]

[0105] [Table 8]

[0106] As can be seen from Table 7, when compared with the solubility of the compound of Formula 1 (free base), the hydrochloride of the compound of Formula 1 was higher, and in particular, the dihydrochloride of the compound of Formula 1 was more soluble than the monohydrochloride crystalline form.

[0107] Therefore, among the hydrochloride salts of the compound of Chemical Formula 1, the dihydrochloride trihydrate crystal form is expected to be the most advantageous in terms of pharmaceutical compositions when considering dissolution and the like.

[0108] In addition, as can be seen from Table 8, the sulfonate of the compound of Chemical Formula 1 was significantly higher than the solubility of the compound of Chemical Formula 1 (free base), and in particular, the crystalline form of the ethanesulfonic anhydride of the compound of Chemical Formula 1 was significantly higher in solubility.

[0109] Therefore, among the sulfonate salts of the compound of Chemical Formula 1, the crystalline form of ethanesulfonic anhydride is expected to be the most advantageous in terms of pharmaceutical compositions when considering dissolution and the like.

Claims

1. A crystalline form of an acid addition salt of a compound of the following formula 1: [Formula 1]

2. 2. The crystalline form of claim 1, wherein the acid addition salt is the hydrochloride salt.

3. The crystalline form is the dihydrochloride trihydrate (2HCl·3H 2 3. The crystalline form of claim 2, wherein the crystalline form is O) crystalline form and has an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles (2θ±0.2°) of 6.4°, 7.1°, 11.1°, 12.8°, and 21.2° when illuminated with a Cu-Kα light source.

4. The crystalline form is the monohydrochloride dihydrate (1HCl.2H 2 3. The crystalline form of claim 2, wherein the crystalline form is an O) crystalline form having an X-ray powder diffraction (XRPD) spectrum comprising peaks at diffraction angles (2θ±0.2°) of 7.0°, 7.9°, 15.8°, 17.2°, 18.6°, 20.6°, 21.3°, and 23.2° when illuminated with a Cu-Kα light source.

5. 3. The crystalline form of claim 2, wherein the crystalline form is a monohydrochloride anhydrate (1HCl) crystalline form of the compound of formula 1, and has an X-ray powder diffraction (XRPD) spectrum containing peaks at diffraction angles of 4.9°, 14.8°, and 21.2° (2θ±0.2°) when irradiated with a Cu-Kα light source.

6. 2. The crystalline form of claim 1, wherein the acid addition salt is a sulfonate salt.

7. 7. The crystalline form of claim 6, wherein the sulfonate salt is a methanesulfonate salt.

8. 8. The crystalline form of claim 7, wherein the crystalline form is a methanesulfonic anhydride (1MsOH) crystalline form of the compound of Formula 1, and has an X-ray powder diffraction (XRPD) spectrum including peaks at diffraction angles (2θ±0.2°) of 11.8°, 17.2°, 19.0°, 20.0°, 22.8°, and 24.0° when irradiated with a Cu-Kα light source.

9. The crystalline form is methanesulfonic acid monohydrate (1MsOH.1H 2 8. The crystalline form of claim 7, wherein the crystalline form is O) crystalline form and has an X-ray powder diffraction (XRPD) spectrum comprising peaks at diffraction angles (2θ±0.2°) of 7.6°, 15.2°, 17.0°, 18.7°, 20.8°, and 22.8° when illuminated with a Cu-Kα light source.

10. 7. The crystalline form of claim 6, wherein the sulfonate salt is an ethanesulfonate salt.

11. The crystalline form of claim 10, wherein the crystalline form is an anhydrous ethanesulfonic acid salt (1EsOH) crystalline form of the compound of Chemical Formula 1, and has an X-ray powder diffraction (XRPD) spectrum including peaks at diffraction angles (2θ±0.2°) of 17.1°, 18.6°, 21.3°, 22.3°, 23.0°, and 23.6° when irradiated with a Cu-Kα light source.

12. 12. A pharmaceutical composition comprising a crystalline form according to any one of claims 1 to 11 and one or more pharma- ceutically acceptable carriers or diluents.

13. The pharmaceutical composition according to claim 12, characterized in that the pharmaceutical composition is used for the treatment or prevention of positive or malignant tumors, inflammatory diseases, or autoimmune diseases such as rheumatoid arthritis induced by epidermal growth factor receptor tyrosine kinase or a mutant thereof.

Citation Information

Patent Citations

  • Novel condensed pyrimidine derivatives with tyrosine kinase activity inhibitory properties

    JP2013529630A

  • Optimized combination therapies and their use for treating cancer and autoimmune diseases

    JP2018512413A

  • Combination of irak4 inhibitor and btk inhibitor

    JP2018514539A

  • Crystalline forms of hydrochloride salts of thienopyrimidine compounds

    JP2019500384A

  • Crystalline forms of thienopyrimidine compounds

    JP2019504046A